Thalidomide.
Prommer
Eric E
EE
Mayo Clinic Arizona, Scottsdale, Arizona, USA.
Twycross
Robert
R
Oxford University, Oxford, United Kingdom.
Mihalyo
Mary
M
Mylan School of Pharmacy, Duquesne University, Pittsburgh, Pennsylvania, USA.
Wilcock
Andrew
A
University of Nottingham, Nottingham, United Kingdom.
D000014:Abnormalities, Drug-Induced / Q000209:etiology* / Q000517:prevention & control; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000517:prevention & control; D002908:Chronic Disease / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D019317:Evidence-Based Medicine; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D007249:Inflammation / Q000188:drug therapy*; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000517:prevention & control; D013792:Thalidomide / Q000008:administration & dosage* / Q000009:adverse effects*
D007155:Immunologic Factors; D013792:Thalidomide